Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
13.1M
-
Number of holders
-
180
-
Total 13F shares, excl. options
-
15.4M
-
Shares change
-
-432K
-
Total reported value, excl. options
-
$1.16B
-
Value change
-
-$26.7M
-
Put/Call ratio
-
1.23
-
Number of buys
-
86
-
Number of sells
-
-80
-
Price
-
$75.66
Significant Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) as of Q2 2018
209 filings reported holding EGRX - EAGLE PHARMACEUTICALS, INC. - Common Stock as of Q2 2018.
EAGLE PHARMACEUTICALS, INC. - Common Stock (EGRX) has 180 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15.4M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (1.89M shares), BlackRock Inc. (1.43M shares), Park West Asset Management LLC (1.1M shares), Hudson Executive Capital LP (971K shares), IRIDIAN ASSET MANAGEMENT LLC/CT (861K shares), STATE STREET CORP (667K shares), VICTORY CAPITAL MANAGEMENT INC (667K shares), VANGUARD GROUP INC (615K shares), LSV ASSET MANAGEMENT (593K shares), and JW Asset Management, LLC (476K shares).
This table shows the top 180 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.